Reviva Pharmaceuticals Holdings, Inc. Investment Income, Interest
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Investment Income, Interest of $176.32 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. investment income, interest for the quarter ending 2026-06-30 was $176.32K, a 671.74% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. investment income, interest for the quarter ending 2026-03-31 was $89.35K, a 3.77% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. investment income, interest for the quarter ending 2025-12-31 was $143.31K, a 202.26% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. investment income, interest for the quarter ending 2025-09-30 was $59.10K, a 11.00% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. investment income, interest for fiscal 2025 was $311.37K, a 13.84% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. investment income, interest for fiscal 2024 was $361.37K, a 9.30% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. investment income, interest for fiscal 2023 was $398.41K.
- Reviva Pharmaceuticals Holdings, Inc. investment income, interest for fiscal 2020 was $105.18K.
| Period end | Investment Income, Interest 2 month | Investment Income, Interest 3 month | Investment Income, Interest 5 month | Investment Income, Interest 6 month | Investment Income, Interest 8 month | Investment Income, Interest 9 month | Investment Income, Interest 11 month | Investment Income, Interest 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $176.32K 10-Q · filed 2026-08-12 | $265.67K 10-Q · filed 2026-08-12 | $408.98K derived: sum of 3 quarters · filed 2026-08-12 | $468.08K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $89.35K 10-Q · filed 2026-05-13 | $232.66K derived: sum of 2 quarters · filed 2026-05-13 | $291.77K derived: sum of 3 quarters · filed 2026-05-13 | $314.61K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $143.31K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $202.41K derived: sum of 2 quarters · filed 2026-03-30 | $225.26K derived: sum of 3 quarters · filed 2026-08-12 | $311.37K 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $59.10K 10-Q · filed 2025-11-13 | $81.95K derived: sum of 2 quarters · filed 2026-08-12 | $168.06K 10-Q · filed 2025-11-13 | $215.47K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $22.85K 10-Q · filed 2026-08-12 | $108.96K 10-Q · filed 2026-08-12 | $156.37K derived: sum of 3 quarters · filed 2026-08-12 | $209.62K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $86.11K 10-Q · filed 2026-05-13 | $133.52K derived: sum of 2 quarters · filed 2026-05-13 | $186.77K derived: sum of 3 quarters · filed 2026-05-13 | $274.38K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $47.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $100.66K derived: sum of 2 quarters · filed 2026-03-30 | $188.27K derived: sum of 3 quarters · filed 2026-03-30 | $361.37K 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $53.25K 10-Q · filed 2025-11-13 | $140.86K derived: sum of 2 quarters · filed 2025-11-13 | $313.96K 10-Q · filed 2025-11-13 | $370.51K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $87.61K 10-Q · filed 2025-08-14 | $260.71K 10-Q · filed 2025-08-14 | $317.27K derived: sum of 3 quarters · filed 2025-08-14 | $409.03K derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $173.10K 10-Q · filed 2025-05-15 | $229.66K derived: sum of 2 quarters · filed 2025-05-15 | $321.42K derived: sum of 3 quarters · filed 2025-05-15 | $424.50K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $56.56K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $148.32K derived: sum of 2 quarters · filed 2025-04-03 | $251.40K derived: sum of 3 quarters · filed 2025-04-03 | $398.41K 10-K · filed 2025-04-03 | ||||
| 2023-09-30 | $91.76K 10-Q · filed 2024-11-14 | $194.84K derived: sum of 2 quarters · filed 2024-11-14 | $341.85K 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $103.08K 10-Q · filed 2024-08-14 | $250.09K 10-Q · filed 2024-08-14 | ||||||
| 2023-03-31 | $147.01K 10-Q · filed 2024-05-14 | |||||||
| 2022-09-30 | $53.15K 10-Q · filed 2023-11-14 | $66.97K derived: sum of 2 quarters · filed 2023-11-14 | $68.71K 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $13.82K 10-Q · filed 2023-08-14 | $15.56K 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | $1.74K 10-Q · filed 2023-05-15 | |||||||
| 2021-03-31 | $148.00 10-Q · filed 2021-05-17 | |||||||
| 2020-12-31 | $105.18K 10-K/A · filed 2021-05-07 | |||||||
| 2020-11-30 | $3.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14 | $13.69K derived: sum of 2 quarters · filed 2021-01-14 | $122.87K 10-Q · filed 2021-01-14 | $372.61K derived: sum of 4 quarters · filed 2021-01-14 | ||||
| 2020-08-31 | $9.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14 | $119.07K 10-Q · filed 2020-10-14 | $368.81K derived: sum of 3 quarters · filed 2020-10-14 | $692.52K derived: sum of 4 quarters · filed 2020-10-14 | ||||
| 2020-05-31 | $109.17K 10-Q · filed 2020-07-07 | $358.92K derived: sum of 2 quarters · filed 2020-07-07 | $682.63K derived: sum of 3 quarters · filed 2020-07-07 | $1.03M derived: sum of 4 quarters · filed 2020-07-07 | ||||
| 2020-02-29 | $249.75K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04 | $573.45K derived: sum of 2 quarters · filed 2020-05-04 | $925.19K derived: sum of 3 quarters · filed 2020-05-04 | $1.32M 10-K · filed 2020-05-04 | ||||
| 2019-12-31 | $201.00 10-K/A · filed 2021-05-07 | |||||||
| 2019-11-30 | $323.70K 10-Q · filed 2020-01-10 | $675.44K derived: sum of 2 quarters · filed 2020-01-10 | $1.07M 10-Q · filed 2021-01-14 | |||||
| 2019-08-31 | $351.74K 10-Q · filed 2019-10-08 | $750.48K 10-Q · filed 2020-10-14 | ||||||
| 2019-05-31 | $398.75K 10-Q · filed 2020-07-07 | |||||||
| 2019-02-28 | $729.50K 10-K · filed 2020-05-04 | |||||||
| 2018-11-30 | $353.26K 10-Q · filed 2020-01-10 | $377.33K derived: sum of 2 quarters · filed 2020-01-10 | $377.33K 10-Q · filed 2020-01-10 | |||||
| 2018-08-31 | $24.07K 10-Q · filed 2019-10-08 | $24.07K 10-Q · filed 2019-10-08 | ||||||
| 2018-05-31 | $0.00 10-Q · filed 2019-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |